Literature DB >> 34866847

Experience With Changing Etiology and Nontransplant Curative Treatment Modalities for Hepatocellular Carcinoma in a Real-Life Setting-A Retrospective Descriptive Analysis.

Suneel Tohra1, Ajay Duseja1, Sunil Taneja1, Naveen Kalra2, Ujjwal Gorsi2, Arunanshu Behera3, Lileswar Kaman3, Divya Dahiya3, Srimanta Sahu1, Balkrishan Sharma1, Virendra Singh1, Radha K Dhiman1, Yogesh Chawla1.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) has variable etiological risk factors. Radiofrequency ablation (RFA) and surgical resection (SR) are frequently used as curative treatment options. In the present study, we assessed the etiological factors and efficacy of RFA and SR in patients with unifocal HCC in a real-life setting.
METHODS: Of 870 patients with HCC seen over a period of nine years, 785 patients were assessed for stage and etiological risk factors. Of these, 110 (14%) patients with single HCC who were either treated with RFA (n = 72) or SR (n = 38) were evaluated for their outcomes in terms of overall survival (OS) and disease-free survival (DFS) over 3 years.
RESULTS: Of 785 patients [median age 60 (range 51-65) years, males (n = 685, 87.3%)] with HCC, viral hepatitis [HBV and HCV with or without alcohol = 502 (63.9%)] was the most common etiology; nonalcoholic steatohepatitis (NASH) and alcohol as an etiology showed increase over the years. About 677 (86.2%) patients had evidence of cirrhosis; NASH and HBV were predominant causes in noncirrhotic patients. Even though the groups were not matched, in 110 patients subjected to either RFA [mean tumor size, 2.2 (1.9-2.8) cm] or SR [mean tumor size, 7.1 (4.8-9.7) cm], tumor progression was observed in 49 (68%) and 16 (42%) patients in RFA and SR groups, respectively, with superior DFS in the SR group (P < 0.01). Of total 31 deaths, 20 (27.8%) deaths were in the RFA group and 11 (28.9%) in the SR group with no difference in OS at 3 years.
CONCLUSION: Viral hepatitis with or without alcohol is the commonest etiological factor for HCC in Northern India; NASH and alcohol are increasing over the years. In a real-life setting, in patients with unifocal HCC, there is no difference in overall 3-year survival subjected to SR or RFA with better DFS in the SR group.
© 2021 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AFP, Alpha Fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CEMR, Contrast-Enhanced Magnetic Resonance Imaging; CLD, Chronic Liver Disease; DFS, Disease-free Survival; HBV, Hepatitis B Virus; HCC, Hepatocellular Carcinoma; HCV, Hepatitis C Virus; LT, Liver Transplantation; NAFLD, Non -Alcoholic Fatty Liver Disease; NASH; NASH, Non-alcoholic Steatohepatitis; OS, Overall Survival; RFA, Radiofrequency Ablation; SR, Surgical Resection; TPCT, Triple-Phase Contrast-enhanced computerized Tomography; alcohol; hepatitis B virus; hepatitis C virus; nonalcoholic fatty liver disease

Year:  2021        PMID: 34866847      PMCID: PMC8617543          DOI: 10.1016/j.jceh.2021.02.002

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  38 in total

1.  Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database.

Authors:  Johannes Uhlig; Cortlandt M Sellers; Stacey M Stein; Hyun S Kim
Journal:  Eur Radiol       Date:  2018-12-17       Impact factor: 5.315

2.  Evaluation of clinical and biochemical parameters in hepatocellular carcinoma: experience from an Indian center.

Authors:  Nitin Saini; Ashish Bhagat; Sanjeev Sharma; Ajay Duseja; Yogesh Chawla
Journal:  Clin Chim Acta       Date:  2006-05-02       Impact factor: 3.786

Review 3.  2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Anil Arora; Radha K Dhiman; Rakesh Aggarwal; Anil C Anand; Prashant Bhangui; Yogesh K Chawla; Siddhartha Datta Gupta; Vinod K Dixit; Ajay Duseja; Naveen Kalra; Premashish Kar; Suyash S Kulkarni; Rakesh Kumar; Manoj Kumar; Ram Madhavan; V G Mohan Prasad; Amar Mukund; Aabha Nagral; Dipanjan Panda; Shashi B Paul; Padaki N Rao; Mohamed Rela; Manoj K Sahu; Vivek A Saraswat; Samir R Shah; Praveen Sharma; Sunil Taneja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-09-23

4.  Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study.

Authors:  Samer Gawrieh; Lara Dakhoul; Ethan Miller; Andrew Scanga; Andrew deLemos; Carla Kettler; Heather Burney; Hao Liu; Hamzah Abu-Sbeih; Naga Chalasani; Julia Wattacheril
Journal:  Aliment Pharmacol Ther       Date:  2019-09-01       Impact factor: 8.171

Review 5.  The global epidemiology of hepatocellular carcinoma: present and future.

Authors:  Katherine A McGlynn; W Thomas London
Journal:  Clin Liver Dis       Date:  2011-05       Impact factor: 6.126

6.  Characteristics of hepatocellular carcinoma in India: a retrospective analysis of 191 cases.

Authors:  R Kumar; M Kumar Saraswat; B Chander Sharma; P Sakhuja; S K Sarin
Journal:  QJM       Date:  2008-04-24

7.  Current management of hepatocellular carcinoma.

Authors:  Ana Maria Crissien; Catherine Frenette
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-03

8.  MicroRNA-125b expression and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection.

Authors:  Tomonari Shimagaki; Tomoharu Yoshizumi; Norifumi Harimoto; Sachiyo Yoshio; Yutaka Naito; Yusuke Yamamoto; Takahiro Ochiya; Yoshihiro Yoshida; Tatsuya Kanto; Yoshihiko Maehara
Journal:  Hepatol Res       Date:  2017-12-05       Impact factor: 4.288

Review 9.  Hepatocellular carcinoma: a review.

Authors:  Julius Balogh; David Victor; Emad H Asham; Sherilyn Gordon Burroughs; Maha Boktour; Ashish Saharia; Xian Li; R Mark Ghobrial; Howard P Monsour
Journal:  J Hepatocell Carcinoma       Date:  2016-10-05

10.  Efficacy of Hepatic Resection vs. Radiofrequency Ablation for Patients With Very-Early-Stage or Early-Stage Hepatocellular Carcinoma: A Population-Based Study With Stratification by Age and Tumor Size.

Authors:  Yi-Quan Jiang; Zi-Xian Wang; Yi-Nan Deng; Yang Yang; Guo-Ying Wang; Gui-Hua Chen
Journal:  Front Oncol       Date:  2019-02-26       Impact factor: 6.244

View more
  3 in total

1.  Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients With Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken.

Authors:  Vaneet Jearth; Prachi S Patil; Shaesta Mehta; Sridhar Sundaram; Vishal Seth; Mahesh Goel; Shraddha Patkar; Munita Bal; Vidya Rao
Journal:  J Clin Exp Hepatol       Date:  2021-11-16

2.  FibroScan-AST (FAST) Score for Nonalcoholic Steatohepatitis - Validation in an Indian Cohort.

Authors:  Arka De; Amarjit Keisham; Saurabh Mishra; Manu Mehta; Nipun Verma; Madhumita Premkumar; Sunil Taneja; Ashim Das; Virendra Singh; Ajay Duseja
Journal:  J Clin Exp Hepatol       Date:  2021-06-15

3.  Comparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfa® and VIVA® Systems.

Authors:  Hiroaki Takaya; Tadashi Namisaki; Kazusuke Matsumoto; Junya Suzuki; Koji Murata; Yuki Tsuji; Keisuke Nakanishi; Kosuke Kaji; Mitsuteru Kitade; Ryuichi Noguchi; Hitoshi Yoshiji
Journal:  J Clin Med       Date:  2022-01-15       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.